IMMUNYO LIMITED

Immunyo Limited is a pioneering health‑care company that makes cutting‑edge cancer immunotherapy accessible to patients worldwide. The firm specialises in Dendritic Cell Therapy (DCT), a minimally invasive, pain‑free treatment that harnesses the body’s own immune system to identify and destroy malignant cells. By isolating a patient’s monocytes, converting them into dendritic cells and priming these guardians with tumour‑specific information, Immunyo enables B‑ and T‑cells to target cancer more precisely than conventional chemotherapy, radiation or surgery, with virtually no side‑effects.

The company’s flagship service is the full DCT protocol, offered at a competitive price of €18 950 and delivered through partner clinics across Europe. Immunyo’s approach, rooted in the Nobel‑prize‑winning work of Ralph M. Steinman, can be used alone or in combination with existing cancer treatments, providing a versatile option for almost all cancer patients. By streamlining the application process and providing dedicated health coordinators, Immunyo ensures that anyone seeking a safer, more effective therapy can receive personalised support from the first enquiry to the final treatment.